Charles Schwab
ENTA icon

Charles Schwab’s Enanta Pharmaceuticals ENTA Stock Holding History

Charles Schwab’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.39M Buy
301,151
+6,180
+2% +$83.1K ﹤0.01% 2536
2026
Q1 		$3.73M Buy
294,971
+76,335
+35% +$1.02M ﹤0.01% 2519
2025
Q4 		$3.45M Buy
218,636
+52,089
+31% +$662K ﹤0.01% 2590
2025
Q3 		$1.99M Buy
166,547
+1,900
+1% +$15.2K ﹤0.01% 2748
2025
Q2 		$1.24M Buy
164,647
+4,846
+3% +$29.1K ﹤0.01% 2830
2025
Q1 		$882K Buy
159,801
+4,974
+3% +$30.7K ﹤0.01% 2883
2024
Q4 		$890K Sell
154,827
-7,571
-5% -$72.6K ﹤0.01% 2955
2024
Q3 		$1.68M Sell
162,398
-1,649
-1% -$21.6K ﹤0.01% 2757
2024
Q2 		$2.13M Buy
164,047
+3,047
+2% +$41.1K ﹤0.01% 2688
2024
Q1 		$2.81M Buy
161,000
+13,669
+9% +$181K ﹤0.01% 2492
2023
Q4 		$1.39M Sell
147,331
-9,291
-6% -$86.6K ﹤0.01% 2725
2023
Q3 		$1.75M Buy
156,622
+4,965
+3% +$80K ﹤0.01% 2639
2023
Q2 		$3.25M Buy
151,657
+3,099
+2% +$91.4K ﹤0.01% 2395
2023
Q1 		$6.01M Buy
148,558
+2,668
+2% +$127K ﹤0.01% 2123
2022
Q4 		$6.79M Buy
145,890
+3,783
+3% +$172K ﹤0.01% 2047
2022
Q3 		$7.37M Buy
142,107
+7,876
+6% +$460K ﹤0.01% 2006
2022
Q2 		$6.35M Sell
134,231
-1,895
-1% -$103K ﹤0.01% 2083
2022
Q1 		$9.69M Buy
136,126
+6,863
+5% +$447K ﹤0.01% 1975
2021
Q4 		$9.67M Buy
129,263
+1,517
+1% +$119K ﹤0.01% 2022
2021
Q3 		$7.26M Buy
127,746
+1,015
+0.8% +$50.2K ﹤0.01% 2190
2021
Q2 		$5.58M Buy
126,731
+2,091
+2% +$102K ﹤0.01% 2299
2021
Q1 		$6.15M Buy
124,640
+3,908
+3% +$195K ﹤0.01% 2193
2020
Q4 		$5.08M Buy
120,732
+2,802
+2% +$123K ﹤0.01% 2203
2020
Q3 		$5.4M Buy
117,930
+3,074
+3% +$149K ﹤0.01% 2022
2020
Q2 		$5.77M Buy
114,856
+7,316
+7% +$379K ﹤0.01% 1959
2020
Q1 		$5.53M Sell
107,540
-1,479
-1% -$78.8K ﹤0.01% 1783
2019
Q4 		$6.74M Buy
109,019
+52
+0% +$3.22K ﹤0.01% 1867
2019
Q3 		$6.55M Buy
108,967
+2,826
+3% +$210K ﹤0.01% 1831
2019
Q2 		$8.96M Buy
106,141
+4,950
+5% +$445K 0.01% 1662
2019
Q1 		$9.67M Buy
101,191
+3,814
+4% +$342K 0.01% 1619
2018
Q4 		$6.9M Sell
97,377
-7,182
-7% -$551K 0.01% 1709
2018
Q3 		$8.94M Buy
104,559
+10,230
+11% +$1.02M 0.01% 1718
2018
Q2 		$10.9M Buy
94,329
+2,835
+3% +$283K 0.01% 1535
2018
Q1 		$7.4M Sell
91,494
-5,778
-6% -$445K 0.01% 1708
2017
Q4 		$5.71M Buy
97,272
+40,853
+72% +$2.05M ﹤0.01% 1865
2017
Q3 		$2.64M Buy
56,419
+2,803
+5% +$113K ﹤0.01% 2186
2017
Q2 		$1.93M Buy
53,616
+304
+0.6% +$9.72K ﹤0.01% 2233
2017
Q1 		$1.64M Buy
53,312
+2,736
+5% +$85.2K ﹤0.01% 2265
2016
Q4 		$1.7M Buy
50,576
+2,464
+5% +$70.6K ﹤0.01% 2245
2016
Q3 		$1.28M Sell
48,112
-4,650
-9% -$108K ﹤0.01% 2327
2016
Q2 		$1.16M Sell
52,762
-73,126
-58% -$1.91M ﹤0.01% 2299
2016
Q1 		$3.7M Sell
125,888
-44,265
-26% -$1.23M ﹤0.01% 1700
2015
Q4 		$5.62M Buy
170,153
+5,513
+3% +$180K 0.01% 1440
2015
Q3 		$5.95M Buy
164,640
+44,716
+37% +$1.92M 0.01% 1360
2015
Q2 		$5.4M Buy
119,924
+45,228
+61% +$1.76M 0.01% 1504
2015
Q1 		$2.29M Buy
74,696
+3,874
+5% +$151K ﹤0.01% 1987
2014
Q4 		$3.6M Buy
70,822
+15,988
+29% +$716K 0.01% 1679
2014
Q3 		$2.17M Buy
54,834
+37,180
+211% +$1.48M ﹤0.01% 1926
2014
Q2 		$761K Buy
17,654
+9,852
+126% +$376K ﹤0.01% 2451
2014
Q1 		$313K Buy
7,802
+180
+2% +$6.54K ﹤0.01% 2784
2013
Q4 		$208K Sell
7,622
-9,284
-55% -$225K ﹤0.01% 2946
2013
Q3 		$401K Buy
+16,906
New +$323K ﹤0.01% 2632

Other funds holding ENTA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Charles Schwab's ENTA Position: Q2 2026 in Review

Charles Schwab increased its Enanta Pharmaceuticals (ENTA) stake by 2.1% in Q2 2026, buying an estimated $83.1K and bringing the position to 301,151 shares worth $4.39M. The position accounts for ﹤0.01% of the portfolio, ranked #2536.

Charles Schwab first reported a position in ENTA in Q3 2013 and has held it in 52 quarters since. The position peaked at $10.9M in Q2 2018. 122 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

  • Charles Schwab held 301,151 shares of Enanta Pharmaceuticals worth $4.39M as of Q2 2026.
  • Charles Schwab bought 6,180 Enanta Pharmaceuticals shares in Q2 2026, an estimated $83.1K.
  • Enanta Pharmaceuticals made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2536 holding.
  • Charles Schwab first reported a position in Enanta Pharmaceuticals in Q3 2013 and has held it in 52 quarters since.
  • Charles Schwab's Enanta Pharmaceuticals position peaked at $10.9M in Q2 2018.
  • 122 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.